Tumor immunology and immunotherapy

Tumor immunology and immunotherapy. Ed. Robert C. Rees. Oxford University Press (2014)


  1. Adaptive T­cell immunity and tumor antigen recognition
  2. Impact of ageing and body mass on cancer immunotherapy outcomes
  3. The potential of natural killer cells in cancer immunotherapy
  4. The tumor microenvironment: The role of tumor­associated macrophages in cancer progression and responses to therapy
  5. ‘Hard’ and ‘soft’ loss of MHC class I expression in cancer cells
  6. Modulation of the adaptive immune system through chronic inflammation and T­regulatory responses
  7. Myeloid­-derived suppressor cells: Immune-­suppressive cells that facilitate tumor progression and promote and deter cancer­associated inflammation
  8. Triggering death receptors to promote cancer cell death
  9. Identification of tumor antigens for clinical evaluation
  10. Viral antigens as targets for prophylactic and therapeutic intervention in cancer
  11. HER2/neu as a target for vaccine and antibody­directed therapies
  12. Pre­clinical evaluation of immunotherapy: The case for prostate cancer and the TRAMP model
  13. Tumor­-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy
  14. Predictive biomarkers to better select patients for cancer immunotherapy
  15. Viral platforms for expression of tumor antigens in cancer immunotherapy
  16. Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies
  17. DNA vaccines
  18. Programming the immune system through childhood infections: MUC1 tumor­associated antigen (TAA) as a disease­associated antigen (DAA)
  19. Vaccination against myeloid leukaemias using newly defined antigens
  20. Immune­checkpoint blockade in cancer immunotherapy
  21. Multi­peptide cancer vaccines for clinical application
  22. Adoptive T­cell therapy using TILs for the treatment of metastatic melanoma
  23. Chimeric antigen receptor gene therapy in cancer
  24. The vaccinal effect of monoclonal antibodies in cancer therapy
  25. Antibody therapies: defining appropriate cell surface epitopes for targeting tumors
  26. Adoptive lymphocyte (stem cell) therapy in cancer
  27. Cancer stem cells (CSCs) and epithelial­to­mesenchymal transition (EMT): Tumor cell plasticity challenges immunotherapy
  28. Immune escape and ageing of the immune system compromises the immune response to tumor antigens

 

[contact-form-7 id=»5168″ title=»Контактная форма 1″]

0

Добавить комментарий

Войти с помощью: 

Ваш e-mail не будет опубликован. Обязательные поля помечены *